Broad Area ALA 1-hour incubation — Competitive Intelligence Brief

Broad Area ALA 1-hour incubation (Broad Area ALA 1-hour incubation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Photodynamic therapy agent. Area: Dermatology.

phase 2 Photodynamic therapy agent Dermatology Small molecule

Target snapshot

Broad Area ALA 1-hour incubation (Broad Area ALA 1-hour incubation) — DUSA Pharmaceuticals, Inc.. ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Broad Area ALA 1-hour incubation TARGET	Broad Area ALA 1-hour incubation	DUSA Pharmaceuticals, Inc.	phase 2	Photodynamic therapy agent
Ameluz 10% Topical Gel	Ameluz 10% Topical Gel	Psoriasis Treatment Center of Central New Jersey	marketed	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer)
TOOKAD VTP	TOOKAD VTP	Steba Biotech S.A.	marketed	Photodynamic therapy agent	Vascular endothelial cells (non-receptor mediated phototoxicity)
BF-200 ALA cream	BF-200 ALA cream	Joint Authority for Päijät-Häme Social and Health Care	marketed	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer generated from aminolevulinic acid)
c-PDT	c-PDT	Galderma R&D	phase 3	Photodynamic therapy agent
MAL 16.8% cream	MAL 16.8% cream	Galderma R&D	phase 3	Photodynamic therapy agent	Protoporphyrin IX (photosensitizer)
Placebo to BF-200 ALA gel	Placebo to BF-200 ALA gel	Biofrontera Bioscience GmbH	phase 3	Photodynamic therapy agent	Protoporphyrin IX (via aminolevulinic acid metabolism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Photodynamic therapy agent class)

1. Galderma R&D · 3 drugs in this class
2. DUSA Pharmaceuticals, Inc. · 2 drugs in this class
3. Biofrontera Bioscience GmbH · 2 drugs in this class
4. Steba Biotech S.A. · 2 drugs in this class
5. National Cancer Center, Korea · 1 drug in this class
6. Photocure · 1 drug in this class
7. Psoriasis Treatment Center of Central New Jersey · 1 drug in this class
8. Joint Authority for Päijät-Häme Social and Health Care · 1 drug in this class